Melatonin supplementation safe and may reduce CV risk related to night shift work: Lancet

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-22 04:15 GMT   |   Update On 2024-05-22 06:41 GMT

Researchers have found that regular use of melatonin supplements is not associated with an increased risk of developing type 2 diabetes or cardiovascular disease (CVD) in adults. This conclusion comes from a comprehensive study involving three large U.S. cohorts, aimed at assessing the long-term cardiometabolic effects of melatonin supplement use. This was published in The Lancet. Diabetes & Endocrinology by Yanping Li. and colleagues.

The use of melatonin supplements has risen significantly in recent years among both children and adults in the USA. However, their long-term effects on cardiometabolic health remain uncertain. To address this gap, researchers analyzed data from the Nurses' Health Study (NHS), Health Professionals Follow-up Study (HPFS), and the Nurses' Health Study II (NHS II) to determine the association between melatonin supplement use and the incidence of type 2 diabetes and cardiovascular disease.

Advertisement

This study included 67,202 women from the NHS, 26,629 men from the HPFS, and 65,241 women from the NHS II. Participants were aged 25-55 years (women) and 45-75 years (men) at baseline, with no prior diagnosis of cancer, cardiovascular disease, or type 2 diabetes. The main outcomes were the incidence of cardiovascular disease and type 2 diabetes, with follow-up periods extending up to 23 years.

Melatonin supplement use was assessed via self-reported questionnaires. The researchers also conducted secondary analyses to evaluate the effects of melatonin use among participants with long-term rotating night shift work, a known risk factor for adverse cardiometabolic outcomes.

• Over the follow-up period, the prevalence of melatonin supplement use doubled, rising from less than 2% in 1998-2007 to over 4% by 2014-2015, with 4.0% usage in men and 5.3% in women.

• The study documented 16,917 incident cardiovascular disease events and 12,730 incident cases of type 2 diabetes across 2,609,068 and 2,701,830 person-years of follow-up, respectively.

• The pooled multivariable-adjusted hazard ratio for cardiovascular disease among melatonin users compared to non-users was 0.94 (95% CI 0.83–1.06, p=0.32), indicating no significant association.

• The pooled multivariable-adjusted hazard ratio for type 2 diabetes was 0.98 (95% CI 0.86–1.12, p=0.80), also showing no significant link between melatonin use and diabetes risk.

• In secondary analyses, melatonin supplement use appeared to attenuate the increased risk of cardiovascular disease associated with long-term rotating night shift work (>5 years) among female nurses (p_interaction=0.013).

The results suggest that regular melatonin supplement use is not associated with an increased risk of type 2 diabetes or cardiovascular disease. This finding provides reassurance to the growing number of individuals using melatonin supplements for sleep-related issues. Notably, the study also highlighted a potential protective effect of melatonin against the cardiometabolic risks associated with long-term shift work, particularly in women.

With up to 23 years of follow-up data from three large cohorts, this study provides strong evidence that melatonin supplement use does not increase the risk of developing type 2 diabetes or cardiovascular disease in middle-aged and older adults. Further research is warranted to explore the potential benefits of melatonin in mitigating risks associated with shift work.

Reference:

Li, Y., Huang, T., Redline, S., Willett, W. C., Manson, J. E., Schernhammer, E. S., & Hu, F. B. (2024). Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies. The Lancet. Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00096-2



Tags:    
Article Source : The Lancet. Diabetes & Endocrinology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News